CERS2 and prostate cancer: In various cancers, LASS2 has been shown to negatively regulate tumorigenesis and metastasis, including bladder cancer [21], prostate cancer [65], breast cancer [66], hepatocellular carcinoma [18], and thyroid cancer [67].